ARS Pharmaceuticals (SPRY) Investor Presentation - Slideshow

Fleming et al. J Allergy Clin Immunol Pract (2014), 4 E. Andrew et al. Prehospital Emergency Care (2018), 5 Data on file from ARS market research NO TREATMENT AVAILABLE ~25% - 50%1, 3, 5 do not administer ~40 - 60%2 of patients delay 1 2 3 4 • Same shelf-life as EpiPen, but also stable at high temperatures • ~10% of cases require multiple doses of epinephrine1 • No risk of needle-related injuries; lacerations2 or cardiotoxic blood vessel injections • 0% critical dosing errors in registration self-administra ...